Introduction Clinicians need to know whether lumbosacral radiculopathy (LRS) can be attributed to work. Therefore the association between work-related risk factors and clinically assessed LRS has to ...

It cites an uncertain benefit and risk profile of suzetrigine in lumbosacral radiculopathy, and doubts on its commercial potential in acute paid ahead of the January 30, 2025, FDA action date for ...

Vertex Pharmaceuticals’ (NASDAQ:VRTX) investigational non-opioid drug, suzetrigine, has met the primary endpoint in a mid-stage study in people with painful lumbosacral radiculopathy (LSR).

An archived webcast will be available on the company's website. About the Phase 2 Suzetrigine Lumbosacral Radiculopathy (LSR) Study This phase 2, 12-week, randomized, double-blind, placebo ...

Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain. The company ...